BRSF logo

Brain Scientific Inc. (BRSF) Análisis de Acciones

Solo con fines informativos. No es asesoramiento financiero. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.

Cotizando a $, Brain Scientific Inc. (BRSF) es una empresa del sector Healthcare valorada en 0. Calificado con 49/100 (cauteloso) en potencial de crecimiento, salud financiera e impulso.

Ultimo analisis: 17 mar 2026
Puntuación de IA de 49/100

Brain Scientific Inc. (BRSF) Resumen de Asistencia Médica y Tuberías

CEOHassan Kotob
Empleados11
Sede CentralSarasota, US
Año de la oferta pública inicial (OPI)2021

Brain Scientific Inc. develops and markets neurology-focused medical devices, including the NeuroCap EEG system and NeuroNet Cloud platform. Operating in the competitive medical device sector, the company targets improved EEG technology and data analysis solutions for neurological applications, while navigating the challenges of a small-cap, OTC-listed entity.

Procedencia de los datos | Datos financieros Análisis cuantitativo NASDAQ Análisis: 17 mar 2026

Tesis de Inversión

Brain Scientific Inc. presents a speculative investment opportunity within the medical device sector. The company's NeuroCap and NeuroEEG products target the EEG market, offering potential improvements in usability and data analysis. With a market capitalization of $0.00B, the company is a micro-cap stock trading on the OTC market, implying higher risk and volatility. A key value driver is the potential adoption of NeuroCap and NeuroEEG by hospitals and clinics seeking more efficient EEG solutions. Growth catalysts include potential FDA approvals for new products and expansion of the NeuroNet Cloud platform. However, the company's negative profit margin of -5753.0% and reliance on OTC markets are significant risk factors. Investors should carefully consider the company's financial position and competitive landscape before investing.

Basado en las finanzas de FMP y el análisis cuantitativo

Puntos clave

  • Market Cap of $0.00B reflects its micro-cap status and potential for high volatility.
  • Gross Margin of 25.3% indicates the profitability of its products before operating expenses.
  • Profit Margin of -5753.0% highlights significant challenges in achieving overall profitability.
  • Beta of 0.36 suggests lower volatility compared to the overall market.
  • Operates in the medical device industry, focusing on neurology-based solutions.

Competidores y Pares

Fortalezas

  • Innovative NeuroCap design.
  • NeuroNet Cloud platform for data analysis.
  • Focus on neurology provides specialization.
  • Proprietary technology and intellectual property.

Debilidades

  • Small market capitalization and limited resources.
  • Negative profit margin and financial instability.
  • Reliance on OTC markets.
  • Limited brand recognition.

Catalizadores

  • Upcoming: Potential FDA approvals for new products or enhancements to existing products.
  • Ongoing: Expansion of the NeuroNet Cloud platform and its integration with other healthcare systems.
  • Ongoing: Strategic partnerships with hospitals and clinics to expand market reach.
  • Potential: International expansion into new markets.
  • Ongoing: Development of new EEG applications beyond traditional diagnostics.

Riesgos

  • Ongoing: Competition from larger, established medical device companies.
  • Potential: Regulatory hurdles and compliance requirements for medical devices.
  • Potential: Technological obsolescence and the emergence of competing technologies.
  • Ongoing: Limited financial resources and negative profit margin.
  • Ongoing: Reliance on OTC markets and the associated risks of limited liquidity and transparency.

Oportunidades de crecimiento

  • Expansion of NeuroNet Cloud Platform: The NeuroNet Cloud platform offers a significant growth opportunity by providing data analytics and storage solutions for EEG data. The market for cloud-based healthcare solutions is expanding rapidly, driven by the increasing adoption of electronic health records and the need for data-driven insights. By expanding the capabilities of NeuroNet Cloud and integrating it with other healthcare systems, Brain Scientific can attract new customers and generate recurring revenue streams. Timeline: Ongoing, with continuous updates and feature additions planned.
  • FDA Approvals for New Products: Obtaining FDA approvals for new products and enhancements to existing products is crucial for Brain Scientific's growth. Regulatory approvals validate the safety and efficacy of the company's devices, allowing them to be marketed and sold to healthcare providers. The timeline for FDA approvals can vary depending on the complexity of the device and the regulatory pathway chosen. Successful approvals can significantly boost the company's revenue and market share. Timeline: Ongoing, with submissions planned for various products.
  • Strategic Partnerships with Hospitals and Clinics: Forming strategic partnerships with hospitals and clinics can provide Brain Scientific with access to a wider customer base and valuable feedback on its products. These partnerships can involve pilot programs, joint research projects, and co-marketing initiatives. By collaborating with healthcare providers, Brain Scientific can demonstrate the value of its products and build long-term relationships. Timeline: Ongoing, with active outreach to potential partners.
  • International Expansion: Expanding into international markets represents a significant growth opportunity for Brain Scientific. The global market for medical devices is vast, and many countries have a growing need for advanced neurological solutions. By obtaining regulatory approvals in key international markets and establishing distribution networks, Brain Scientific can diversify its revenue streams and reduce its reliance on the US market. Timeline: Potential, with initial focus on select international markets.
  • Development of New EEG Applications: Exploring new applications for EEG technology beyond traditional diagnostics can unlock new growth opportunities for Brain Scientific. This could involve developing EEG-based solutions for monitoring sleep disorders, assessing cognitive function, or providing neurofeedback therapy. By expanding the applications of its technology, Brain Scientific can reach new customer segments and establish itself as a leader in the field of EEG innovation. Timeline: Ongoing, with research and development efforts focused on new applications.

Oportunidades

  • Expansion of NeuroNet Cloud platform.
  • FDA approvals for new products.
  • Strategic partnerships with hospitals and clinics.
  • International expansion.

Amenazas

  • Competition from larger, established medical device companies.
  • Regulatory hurdles and compliance requirements.
  • Technological obsolescence.
  • Economic downturn and reduced healthcare spending.

Ventajas competitivas

  • Proprietary NeuroCap design offers potential advantages in usability and comfort.
  • NeuroNet Cloud platform provides a data analytics and storage solution that can create customer stickiness.
  • Focus on neurology provides specialization and expertise in a niche market.
  • Intellectual property protection through patents and trademarks.

Acerca de BRSF

Founded in 2013 and headquartered in Sarasota, Florida, Brain Scientific Inc. is a medtech company specializing in neurology-focused medical devices. The company's core mission is to innovate and provide advanced solutions for the diagnosis and monitoring of neurological conditions. Its key product, NeuroCap, is a disposable EEG cap designed to improve the efficiency and accuracy of electroencephalography procedures. NeuroCap aims to address the limitations of traditional EEG systems by offering a more comfortable and user-friendly experience. Complementing NeuroCap is NeuroEEG, a clinical-grade device used to acquire, record, transmit, and display electrical brain activity in patients of all ages. The company also offers NeuroNet Cloud, a platform for storing and analyzing brain data, providing clinicians with tools for enhanced diagnostics and research. Beyond its neurology focus, Brain Scientific also develops motor platforms, including an ultra-precise micro dosing pump and other motion products. The company operates primarily in the United States, targeting hospitals, clinics, and research institutions. Brain Scientific's strategy centers on combining innovative hardware with data analytics to improve patient outcomes in neurology.

Qué hacen

  • Develops and markets the NeuroCap, a disposable EEG cap designed for improved comfort and ease of use.
  • Offers NeuroEEG, a clinical-grade device for recording and displaying electrical brain activity.
  • Provides NeuroNet Cloud, a platform for storing and analyzing EEG data.
  • Develops motor platforms, including micro dosing pumps.
  • Focuses on neurology-based medical devices.
  • Aims to improve the efficiency and accuracy of EEG procedures.

Modelo de Negocio

  • Sells NeuroCap and NeuroEEG devices to hospitals, clinics, and research institutions.
  • Generates revenue from subscriptions to the NeuroNet Cloud platform.
  • Potentially generates revenue from the sale of motor platforms and related products.
  • Focuses on direct sales and partnerships with distributors.

Contexto de la Industria

Brain Scientific Inc. operates within the medical device industry, specifically targeting the neurology segment. The global medical device market is projected to reach trillions of dollars by 2026, driven by technological advancements and an aging population. The EEG market, in particular, is expected to grow as neurological disorders become more prevalent. Brain Scientific competes with larger, established medical device companies, as well as smaller, specialized firms. The company's success depends on its ability to innovate, obtain regulatory approvals, and effectively market its products to healthcare providers.

Clientes Clave

  • Hospitals
  • Clinics
  • Research institutions
  • Neurologists
Confianza de la IA: 79% Actualizado: 17 mar 2026

Finanzas

Gráfico e información

Precio de la acción de Brain Scientific Inc. (BRSF): Price data unavailable

Últimas noticias

Consenso de analistas

Calificación de Consenso

Recomendaciones agregadas de Compra/Mantener/Vender de Benzinga, Yahoo Finance y Finnhub para BRSF.

Objetivos de Precios

Análisis del precio objetivo de Wall Street para BRSF.

MoonshotScore

49/100

¿Qué significa esta puntuación?

El MoonshotScore califica el potencial de crecimiento de BRSF en una escala de 0 a 100 en múltiples factores, incluyendo innovación, disrupción del mercado, salud financiera e impulso.

Liderazgo: Hassan Kotob

CEO

Hassan Kotob serves as the CEO of Brain Scientific Inc. His background includes experience in managing and growing technology-focused companies. He has a track record of leading teams and driving innovation in the medical device sector. Kotob's expertise spans strategic planning, product development, and market expansion. He is responsible for overseeing all aspects of Brain Scientific's operations and executing the company's growth strategy. His leadership is focused on advancing the company's neurology-focused medical devices and expanding its market presence.

Historial: Under Hassan Kotob's leadership, Brain Scientific has focused on developing and commercializing its NeuroCap and NeuroEEG products. Key milestones include the launch of the NeuroNet Cloud platform and efforts to secure regulatory approvals for new products. Kotob has also overseen the company's strategic partnerships and market expansion initiatives. His focus has been on driving innovation and building a strong foundation for future growth.

Información del mercado OTC de BRSF

The OTC Other tier represents the lowest tier of the OTC market, indicating that Brain Scientific Inc. may not meet the minimum financial or disclosure requirements for higher tiers like OTCQB or OTCQX. Companies in this tier may have limited financial reporting, and investors should exercise caution due to the increased risk of fraud and manipulation. Trading on the OTC Other tier differs significantly from trading on major exchanges like the NYSE or NASDAQ, which have stricter listing standards and regulatory oversight.

  • Nivel OTC: OTC Other
  • Estado de divulgación: Unknown
Liquidez: Liquidity on the OTC market can be limited, especially for micro-cap stocks like Brain Scientific Inc. This can result in wider bid-ask spreads and difficulty in executing large trades without significantly impacting the stock price. Investors should be aware of the potential for price volatility and consider using limit orders to manage their risk. The low trading volume may make it challenging to enter or exit positions quickly.
Factores de riesgo OTC:
  • Limited financial disclosure and transparency.
  • Higher risk of fraud and manipulation.
  • Lower liquidity and wider bid-ask spreads.
  • Greater price volatility.
  • Potential delisting or trading suspension.
Lista de verificación de diligencia debida:
  • Verify the company's financial statements and SEC filings (if available).
  • Research the company's management team and their track record.
  • Assess the company's business model and competitive landscape.
  • Review the company's OTC Markets profile and disclosure statements.
  • Consult with a qualified financial advisor.
  • Understand the risks associated with investing in OTC stocks.
  • Check for any regulatory actions or legal proceedings against the company.
Señales de legitimidad:
  • Development of proprietary technology (NeuroCap and NeuroNet Cloud).
  • Focus on a specific niche market (neurology).
  • Presence of a CEO with relevant experience.
  • Company headquarters in the United States.
  • Efforts to secure regulatory approvals for its products.

Acciones de Brain Scientific Inc.: Preguntas Clave Respondidas

¿Cuáles son los factores clave para evaluar BRSF?

Brain Scientific Inc. (BRSF) actualmente tiene una puntuación IA de 49/100, indicando puntuación baja. Fortaleza clave: Innovative NeuroCap design.. Riesgo principal a monitorear: Ongoing: Competition from larger, established medical device companies.. Esto no es asesoramiento financiero.

¿Qué es el MoonshotScore de BRSF?

BRSF actualmente puntúa 49/100 (Grado D) en el MoonshotScore, lo que sugiere calificación baja. La puntuación evalúa el potencial de crecimiento, la salud financiera, el impulso del mercado y los factores de riesgo en 9 KPIs cuantitativos. Se recalcula diariamente con los últimos datos del mercado. Esta puntuación es solo informativa.

¿Con qué frecuencia se actualizan los datos de BRSF?

Los precios de BRSF se actualizan en tiempo real durante el horario del mercado estadounidense (9:30-16:00 ET, días laborables). Los fundamentales se actualizan después de los informes trimestrales o anuales. Las calificaciones de analistas y las perspectivas de IA se actualizan diariamente. Las noticias se agregan continuamente de fuentes financieras.

¿Qué dicen los analistas sobre BRSF?

La cobertura de analistas para BRSF incluye calificaciones de consenso (compra, mantener, venta), objetivos de precio a 12 meses y estimaciones de ganancias de las principales firmas de investigación. Consulte la sección de Consenso de Analistas en esta página.

¿Cuáles son los riesgos de invertir en BRSF?

Las categorías de riesgo para BRSF incluyen riesgo de mercado, riesgo específico de la empresa (gestión, competencia), riesgo financiero (deuda, consumo de efectivo) y riesgo macroeconómico (tasas, inflación). Un riesgo clave identificado: Ongoing: Competition from larger, established medical device companies.. Un beta superior a 1,0 indica mayor volatilidad que el S&P 500. Revise la sección de Factores de Riesgo en esta página. Todas las inversiones conllevan riesgo de pérdida.

¿Cuál es la relación P/E de BRSF?

La relación P/E para BRSF compara el precio actual de la acción con sus ganancias por acción. Un P/E más alto puede indicar expectativas de crecimiento, mientras que un P/E más bajo puede sugerir valor. Consulte la pestaña de Financieros para métricas actuales.

¿Está BRSF sobrevalorada o infravalorada?

Determinar si Brain Scientific Inc. (BRSF) está sobrevalorada o infravalorada requiere examinar múltiples métricas. Compare los ratios de valoración (P/E, P/S, EV/EBITDA) con pares del sector. Esto no es asesoramiento financiero.

¿Cuál es el rendimiento por dividendo de BRSF?

Brain Scientific Inc. (BRSF) actualmente no paga un dividendo regular, o los datos de rendimiento no están disponibles. Consulte la pestaña de Financieros para información actual.

Descargo de responsabilidad: Este contenido es solo para fines informativos y no constituye asesoramiento de inversión. Siempre haga su propia investigación y consulte a un asesor financiero.

Recursos Oficiales

Análisis actualizado el Puntuación de IA actualizada diariamente
Fuentes de Datos y Metodología
Datos de mercado proporcionados por Financial Modeling Prep y Yahoo Finance. Análisis de IA por algoritmos propietarios de Stock Expert AI. Indicadores técnicos mediante cálculos estándar de la industria. Última actualización: .

Datos proporcionados solo con fines informativos.

Notas de análisis
  • Information is based on available data as of 2026-03-17.
  • OTC market data may be limited and less reliable than data from major exchanges.
  • AI analysis is pending and may provide additional insights.
Fuentes de datos

Popular Stocks